$24.50
2.16% yesterday
Nasdaq, Dec 11, 10:00 pm CET
ISIN
US38870X1046
Symbol
LENZ

Graphite Bio Inc Stock price

$24.50
-1.95 7.37% 1M
-5.50 18.33% 6M
-4.37 15.14% YTD
-8.52 25.80% 1Y
+9.50 63.30% 3Y
-63.06 72.02% 5Y
-63.06 72.02% 10Y
-63.06 72.02% 20Y
Nasdaq, Closing price Thu, Dec 11 2025
-0.54 2.16%
ISIN
US38870X1046
Symbol
LENZ
Industry

Key metrics

Basic
Market capitalization
$766.6m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
43.8 | 44.1
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
$7.21
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
-308.1% | -37.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$17.5m | $17.4m
EBITDA
$-67.7m | $-79.0m
EBIT
$-67.9m | $-83.5m
Net Income
$-58.9m | -
Free Cash Flow
$-46.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
1.6% | -35.0%
EBIT
1.5% | -42.6%
Net Income
1.9% | -
Free Cash Flow
52.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-386.8% | -454.2%
EBIT
-388.0%
Net
-336.5% | -
Free Cash Flow
-263.8%
Financial Health
Equity Ratio
94.8%
Return on Equity
-24.4%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
$-2.1
FCF per Share
-
Short interest
43.8%
Employees
-
Rev per Employee
-
Show more

Is Graphite Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Graphite Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Graphite Bio Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Graphite Bio Inc forecast:

Buy
93%
Hold
7%

Financial data from Graphite Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
18 18
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
79% 79%
348%
- Research and Development Expense 25 25
3% 3%
140%
-68 -68
2% 2%
-387%
- Depreciation and Amortization 0.21 0.21
24% 24%
1%
EBIT (Operating Income) EBIT -68 -68
2% 2%
-388%
Net Profit -59 -59
2% 2%
-336%

In millions USD.

Don't miss a Thing! We will send you all news about Graphite Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Graphite Bio Inc Stock News

Neutral
Seeking Alpha
8 days ago
LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral
GlobeNewsWire
11 days ago
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ
Neutral
GlobeNewsWire
17 days ago
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following...
More Graphite Bio Inc News

Company Profile

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Evert Schimmelpennink
Founded 2017
Website lenz-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today